A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Required: PD-L1 (CD274) overexpression (PD-L1 ≥ 1% Tumor Cell (TC) score)

measurable PD-L1 ≥ 1% Tumor Cell (TC) score by the investigational PD-L1 immunohistochemistry (IHC) assay VENTANA PD-L1 (SP263) CDx Assay conducted by central laboratory

Excluded: EGFR sensitizing mutation

Participants with epidermal growth factor receptor (EGFR)...mutations that are sensitive to available targeted inhibitor therapy

Excluded: ALK fusion

Participants with...anaplastic lymphoma kinase (ALK)...mutations that are sensitive to available targeted inhibitor therapy

Excluded: ROS1 fusion

Participants with...ROS-1 mutations that are sensitive to available targeted inhibitor therapy

Excluded: BRAF V600E

Participants with known BRAFV600E mutations, that are sensitive to available targeted inhibitor therapy

Excluded: RET activating mutation

participants with known activating rearranged during transfection (RET) mutations...are excluded

Excluded: NTRK1 fusion

participants with known...neurotrophic tyrosine receptor kinase (NTRK) fusion gene alterations are excluded

Excluded: NTRK2 fusion

participants with known...neurotrophic tyrosine receptor kinase (NTRK) fusion gene alterations are excluded

Excluded: NTRK3 fusion

participants with known...neurotrophic tyrosine receptor kinase (NTRK) fusion gene alterations are excluded

Cannot have received: anti-PD-1 therapy

prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or other antibody or drug targeting T-cell co-stimulation or checkpoint pathways

Cannot have received: anti-PD-L1 therapy

prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or other antibody or drug targeting T-cell co-stimulation or checkpoint pathways

Cannot have received: anti-PD-L2 therapy

prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or other antibody or drug targeting T-cell co-stimulation or checkpoint pathways

Cannot have received: anti-CTLA-4 therapy

prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or other antibody or drug targeting T-cell co-stimulation or checkpoint pathways

Cannot have received: checkpoint inhibitor

prior treatment with...other antibody or drug targeting T-cell co-stimulation or checkpoint pathways